Global Leading Market Research Publisher QYResearch announces the release of its latest report “PARP1 Antibody – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global PARP1 Antibody market, including market size, share, demand, industry development status, and forecasts for the next few years.
The global market for PARP1 Antibody was estimated to be worth US38millionin2025andisprojectedtoreachUS38millionin2025andisprojectedtoreachUS60 million by 2032, growing at a CAGR of 6.5% from 2026 to 2032. For cancer researchers, DNA repair biologists, and drug discovery scientists, the core business imperative lies in selecting PARP1 antibodies that address the critical need for detecting and quantifying poly (ADP-ribose) polymerase 1 (PARP1), a nuclear enzyme involved in DNA damage repair (base excision repair (BER), single-strand break repair), chromatin remodeling, transcription regulation, and programmed cell death (apoptosis). PARP1 is a validated therapeutic target for BRCA1/2-mutant breast, ovarian, prostate, and pancreatic cancers (PARP inhibitors: olaparib, niraparib, rucaparib, talazoparib). PARP1 antibody detects full-length PARP1 (116 kDa) and cleaved PARP1 (89 kDa, a hallmark of caspase-mediated apoptosis). PARP1 antibody (rabbit polyclonal, mouse/rabbit monoclonal) is validated for Western Blot (WB), Immunohistochemistry (IHC), Immunofluorescence (IF), Immunoprecipitation (IP), and ELISA. Applications: cancer research (PARP inhibitor efficacy), DNA repair studies, apoptosis detection (cleaved PARP1), drug development, and toxicology.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/releases/5985639/parp1-antibody
The PARP1 Antibody market is segmented as below:
Merck
Thermo Fisher Scientific
Bio-Rad
GeneTex
Bioss
BosterBio
RayBiotech
Leading Biology
LifeSpan BioSciences
OriGene Technologies
NSJ Bioreagents
Abcam
ProSci
Abnova Corporation
HUABIO
EpiGentek
Cell Signaling Technology
Biobyt
Jingjie PTM BioLab
Segment by Type
Monoclonal
Polyclonal
Segment by Application
Immunochemistry (IHC)
Immunofluorescence (IF)
Immunoprecipitation (IP)
Western Blot (WB)
ELISA
Others
1. Market Drivers: PARP Inhibitor Clinical Use, DNA Repair Research, and Apoptosis Detection
Several powerful forces are driving the PARP1 antibody market:
PARP inhibitors in oncology – FDA approved PARP inhibitors for BRCA-mutated breast, ovarian, pancreatic, prostate cancer. Antibody for IHC (biomarker expression), preclinical efficacy studies (tumor xenografts). Expanded indications.
DNA damage response (DDR) and repair research – PARP1 central role in base excision repair (BER). Antibody for protein-protein interaction, ChIP (chromatin immunoprecipitation).
Apoptosis and caspase activation – Cleaved PARP1 (89 kDa) marker of apoptosis. Antibody (cleaved PARP1 specific) for cell death studies (drug toxicity, cancer therapy).
Recent market data (December 2025): According to Global Info Research analysis, monoclonal PARP1 antibodies dominate with approximately 60% revenue share (superior specificity, batch consistency, cleaved-specific). Polyclonal 40% share (higher sensitivity). Western Blot (WB) largest application (45% share) (full-length and cleaved detection). Immunohistochemistry (IHC) 25% share (tissue expression, biomarker). Immunoprecipitation (IP) 10% share (protein complex). Immunofluorescence (IF) 10% share (subcellular localization). ELISA 5% share. Others 5%. North America largest market (45% share) (PARP inhibitor clinical use, oncology research). Europe 30% share. Asia-Pacific 20% share. Cell Signaling Technology (CST), Abcam, Merck, Thermo Fisher, Santa Cruz (not listed), Novus leading suppliers.
2. Antibody Types and Specifications
| Type | Host | Specificity | Cleaved PARP1 Detection | Applications | Price | Share |
|---|---|---|---|---|---|---|
| Monoclonal | Rabbit, mouse | Full-length & cleaved | Some clones (specific) | WB, IHC, IF, IP | US$300-600 | ~60% |
| Polyclonal | Rabbit | Full-length (may detect cleaved) | Non-specific | WB, IHC | US$200-450 | ~40% |
Key specifications: Target (PARP1, PARP-1, ADP-ribosyltransferase diphtheria toxin-like 1 (ARTD1)). Host (rabbit, mouse). Clone (monoclonal (CST 9542, 46D11)). Reactivity (human, mouse, rat). Applications validated (WB, IHC, IF, IP, ChIP). Conjugation (unconjugated, HRP, Biotin, FITC, Alexa Fluor). Recommended dilution (WB 1:500-1:2000, IHC 1:100-1:500). Positive control (HeLa, HEK293T, MCF7, Jurkat, etoposide-treated (apoptosis) lysate). Cleaved PARP1 specific antibody (CST #5625, Abcam ab32064) recognizes only 89 kDa fragment.
Exclusive observation (Global Info Research analysis): PARP1 antibody market is dominated by Cell Signaling Technology (CST) and Abcam. CST #9542 (rabbit monoclonal, full-length) is widely cited. CST #5625 (cleaved PARP1-specific) for apoptosis. Proteintech not listed but also supplier. Chinese suppliers (Bioss, HUABIO, Jingjie, Biobyt, Abnova (Taiwan)) lower cost (30-50% less). Cleaved-specific monoclonal antibodies require specific validation (no cross-reactivity with full-length PARP1).
User case – Western Blot (December 2025): Cancer research lab (US) treats breast cancer cells (MCF7) with PARP inhibitor (olaparib) plus DNA damaging agent (cisplatin). Cell lysates, SDS-PAGE, transfer, primary antibody (CST #9542 rabbit monoclonal PARP1, 1:1000; CST #5625 cleaved PARP1, 1:1000), secondary anti-rabbit HRP. Detection ECL. Measure full-length (116 kDa) decrease, cleaved PARP1 (89 kDa) increase (apoptosis).
User case – Immunohistochemistry (IHC) (January 2026): Pathology lab (China) stains ovarian cancer tissue microarray (TMA) for PARP1 (prognostic, PARP inhibitor response). FFPE sections, antigen retrieval, primary antibody (Abcam rabbit monoclonal PARP1 (EPR21898), 1:200), secondary HRP polymer, DAB detection.
3. Technical Challenges
Cross-reactivity with other PARP family members (PARP2, PARP3) – PARP1 shares homology with PARP2 (69% in catalytic domain). Antibody specificity validation. Monoclonal preferable.
Cleaved PARP1 antibody specificity – Cleaved PARP1-specific antibody must not recognize full-length (116 kDa). Validated by WB (apoptosis induced samples).
Technical difficulty – IHC optimization for FFPE: PARP1 antigen retrieval (pressure cooker EDTA buffer). Clone specific (CST 9542 validated for IHC). Titration.
Technical development (October 2025): CST introduced rabbit monoclonal PARP1 (cleaved-specific) with higher affinity (1:2000 dilution for WB) and validated for IHC (FFPE). Compatible with automated IHC stainer (Leica, Roche).
4. Competitive Landscape
Key players include: Merck (Germany – Sigma), Thermo Fisher Scientific (US – Invitrogen), Bio-Rad (US), GeneTex (US), Bioss (China), BosterBio (US), RayBiotech (US), Leading Biology (US), LifeSpan BioSciences (US), OriGene Technologies (US), NSJ Bioreagents (US), Abcam (UK), ProSci (US), Abnova Corporation (Taiwan), HUABIO (China), EpiGentek (US), Cell Signaling Technology (US – CST), Biobyt (China), Jingjie PTM BioLab (China). CST, Abcam leaders.
Regional dynamics: North America (CST, Thermo Fisher, Merck, Bio-Rad) largest market. Europe (Abcam). China (Bioss, HUABIO, Abnova, Biobyt, Jingjie). PARP inhibitor clinical use drives research demand.
5. Outlook
PARP1 antibody market will grow at 6.5% CAGR to US$60 million by 2032, driven by PARP inhibitor expansion (beyond BRCA), DNA repair research, and apoptosis studies. Technology trends: cleaved-specific monoclonal (high specificity), multiplex IHC (PARP1 + γH2AX), and digital spatial profiling (NanoString GeoMx). Asia-Pacific growth 7-8% CAGR.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
